Loading
Life sciences · Journal article
Cell Death and Disease · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Regulated cell death (RCD) programs in cancer have traditionally been framed as discrete pathways defined by signature effectors, including caspases (apoptosis), RIPK1–RIPK3–MLKL (necroptosis), gasdermins (pyroptosis), lipid peroxidation control nodes (ferroptosis), PARP1–AIF/MIF (parthanatos), and FDX1-dependent lipoylation stress (cuproptosis). Here, we advance an integrated view in which these programs function as a configurable decision network rather than isolated routes. Therapeutic and microenvironmental inputs, such as death ligands, chemoradiotherapy, targeted agents, PARP inhibition, copper ionophores, nutrient/oxidative stress, extracellular matrix detachment, and cytotoxic T-cell pressure, converge on shared hub modules that act as rheostats, routing cells toward distinct execution outcomes or into drug-tolerant persister states. This circuit-level framing explains context-dependent switching and mixed phenotypes, including caspase-8/c-FLIP control of apoptosis–necroptosis, caspase–gasdermin coupling of apoptosis–pyroptosis, and metabolic–redox tuning of ferroptosis susceptibility via SLC7A11–GPX4–ACSL4–FSP1 and autophagy-linked lipid/iron handling. We outline a biomarker and functional assay framework to map tumor death wiring from biopsies and organoid challenges, enabling rational combination strategies that exploit death program plasticity while anticipating resistance and inflammatory toxicities.